<DOC>
	<DOC>NCT02986594</DOC>
	<brief_summary>In this clinical cohort study, the investigators observe the efficacy of low molecular weight heparin in the treatment of thrombophilia with recurrent pregnancy loss with a prospective randomized controlled trial.</brief_summary>
	<brief_title>Diagnosis and Treatment Strategy of Recurrent Spontaneous Abortion Associated With Thrombophilla</brief_title>
	<detailed_description />
	<mesh_term>Thrombophilia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<criteria>Woman who had their Second miscarriage before 12(th) week of gestation.The patient who is diagnosed as thrombophilia with recurrent pregnancy loss. Signed consent form. 1. having experiencedsevere allergies, trauma history and/or operation history within 3 months 2. with a history of mental illness and/or family history of mental illness 3. limb disabled 4. taking medicine within one month 5. suffering major events or having mood swings 6. with a history of recurrent pregnancy loss 7. having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine rotine) 8. Chromosome aberrations in anyone of the couple. 9. patients who have drug contraindications</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>